Organization | Chimeric Therapies

Chimeric Therapies Report issue

Contributed to NME For profit Phase 1 Phase 3

Founded: Laguna Niguel CA United States (1996)

Status: Defunct (2001)

Organization Overview

First Clinical Trial

2000

NCT00004255

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Chimeric Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (8)

allogeneic bone marrow (1 trial)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

methylprednisolone (medrol) (1 trial)

sargramostim (leukine) (1 trial)

tacrolimus (prograf) (1 trial)

Drugs in Phase 1 Trials (1)

chm-1101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Graft vs Host Disease (Phase 3)

Leukemia (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 9